Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Operating Leases (2019 - 2022)

Rein Therapeutics filings provide 4 years of Operating Leases readings, the most recent being $217000.0 for Q3 2022.

  • For the quarter ending Q3 2022, Operating Leases rose 119.19% year-over-year to $217000.0, compared with a TTM value of $217000.0 through Sep 2022, up 119.19%, and an annual FY2021 reading of $69000.0, changed N/A over the prior year.
  • Operating Leases hit $217000.0 in Q3 2022 for Rein Therapeutics, roughly flat from $217000.0 in the prior quarter.
  • The five-year high for Operating Leases was $4.9 million in Q1 2019, with the low at $69000.0 in Q4 2021.
  • Median Operating Leases over the past 4 years was $2.2 million (2020), compared with a mean of $2.4 million.
  • The sharpest move saw Operating Leases crashed 97.64% in 2021, then soared 119.19% in 2022.
  • Year by year, Operating Leases stood at $4.6 million in 2019, then decreased by 8.5% to $4.2 million in 2020, then plummeted by 98.36% to $69000.0 in 2021, then soared by 214.49% to $217000.0 in 2022.
  • According to Business Quant data, Operating Leases over the past three periods came in at $217000.0, $217000.0, and $217000.0 for Q3 2022, Q2 2022, and Q1 2022 respectively.